Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 15, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 780 Common Stock at $499.77 ($389,824) on September 15, 2026; holds 333,163 after (Indirect).
- Open-market sale: disposed of 3,711 Common Stock at $500.68 ($1,858,019) on September 15, 2026; holds 329,452 after (Indirect).
- Open-market sale: disposed of 2,689 Common Stock at $501.66 ($1,348,970) on September 15, 2026; holds 326,763 after (Indirect).
- Open-market sale: disposed of 825 Common Stock at $502.57 ($414,620) on September 15, 2026; holds 325,938 after (Indirect).
- Open-market sale: disposed of 845 Common Stock at $503.80 ($425,715) on September 15, 2026; holds 325,093 after (Indirect).
- Open-market sale: disposed of 650 Common Stock at $504.57 ($327,971) on September 15, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 15, 2026; holds 432,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,765,119 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-15 | Open-market sale | Common Stock | 780 | $500 | $389.8K | 333,163 |
| 2026-09-15 | Open-market sale | Common Stock | 3,711 | $501 | $1.9M | 329,452 |
| 2026-09-15 | Open-market sale | Common Stock | 2,689 | $502 | $1.3M | 326,763 |
| 2026-09-15 | Open-market sale | Common Stock | 825 | $503 | $414.6K | 325,938 |
| 2026-09-15 | Open-market sale | Common Stock | 845 | $504 | $425.7K | 325,093 |
| 2026-09-15 | Open-market sale | Common Stock | 650 | $505 | $328.0K | 324,443 |
| 2026-09-15 | Option exercise/conversion | Stock Option | 9,500 | — | — | 432,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (9,500 shares) |
| 2026-09-15 | Open-market sale (780 shares) |
| 2026-09-15 | Open-market sale (3,711 shares) |
| 2026-09-15 | Open-market sale (2,689 shares) |
| 2026-09-15 | Open-market sale (825 shares) |
| 2026-09-15 | Open-market sale (845 shares) |
| 2026-09-15 | Open-market sale (650 shares) |
| 2026-09-15 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.